-

12:45:01 PM

WVE Stock News

WVE - Wave Life Sciences Ltd.

09/28/23 4:15 PM

Nasdaq : WVE

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave’s best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK WVE-006 – industry’s first-ever RNA editing clinical candidate – on

RHEA-AI

neutral

09/25/23 8:30 AM

Nasdaq : WVE

conferences

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive

RHEA-AI

neutral

09/06/23 8:30 AM

Nasdaq : WVE

conferences

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive

RHEA-AI

neutral

09/05/23 7:30 AM

Nasdaq : WVE

conferencesclinical trial

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”

WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce levels of mutant Z-AAT protein, thereby addressing alpha-1 antitrypsin deficiency-related lung

RHEA-AI

neutral

08/03/23 7:30 AM

Nasdaq : WVE

earnings

Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic candidate (WVE-N531) with best-in-class exon skipping clinical data is on track to enter a potentially

RHEA-AI

neutral

07/27/23 8:30 AM

Nasdaq : WVE

earnings

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday,

RHEA-AI

neutral

06/26/23 8:30 AM

Nasdaq : WVE

Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the company has been added to the small-cap Russell

RHEA-AI

neutral

05/23/23 7:30 AM

Nasdaq : WVE

clinical trial

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical benefit compared with placebo; additionally, poly(GP) reductions did not correlate with clinical

RHEA-AI

neutral

05/16/23 8:30 AM

Nasdaq : WVE

Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is designed to restore healthy, wild-type AAT protein Best-in-class exon skipping clinical data for WVE-N531

RHEA-AI

neutral

05/03/23 7:30 AM

Nasdaq : WVE

earnings

Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human study for WVE-006, the industry’s first RNA editing clinical candidate Planning for potentially

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

WVE Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttps://www.wavelifesciences.com/
Security nameWave Life Sciences Ltd.
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountrySingapore

About Wave Life Sciences Ltd.

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.